Georges Khoury

Melbourne, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Common Acquisition of Broadly Neutralizing Antibodies in an HTLV-1c+ First Nations Cohort from Central Australia.

Common Acquisition of Broadly Neutralizing Antibodies in an HTLV-1c+ First Nations Cohort from Central Australia.

Journal: Viruses
Published: February 25, 2026

Immunophenotype and proviral landscape of HTLV-1c infection and pulmonary disease.

Immunophenotype and proviral landscape of HTLV-1c infection and pulmonary disease.

Journal: EBioMedicine
Published: February 23, 2026

High level of genomic divergence in orf-I p12 and hbz genes of HTLV-1 subtype-C in Central Australia.

High level of genomic divergence in orf-I p12 and hbz genes of HTLV-1 subtype-C in Central Australia.

Journal: Retrovirology
Published: March 18, 2024

A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.

A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.

Journal: Science immunology
Published: March 31, 2022

Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.

Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.

Journal: Frontiers in cellular and infection microbiology
Published: January 15, 2022

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo.

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo.

Journal: Cell
Published: January 10, 2022

Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s).

Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s).

Journal: Viruses
Published: April 28, 2021

Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.

Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.

Journal: Journal of virology
Published: April 15, 2021

The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency.

The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency.

Journal: Frontiers in genetics
Published: March 15, 2021

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.

Journal: EBioMedicine
Published: October 23, 2020

Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure.

Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure.

Journal: EBioMedicine
Published: October 21, 2020

Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.

Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.

Journal: The Lancet. Infectious diseases
Published: February 16, 2020
Showing 1-12 of 28

Last Updated: 09/26/2026